ARWR Quote, Financials, Valuation and Earnings

Celcuity, Inc. has a net margin of 6.29% compared to Arrowhead Pharmaceuticals, Inc.'s net margin of --. Arrowhead Pharmaceuticals, Inc.'s return on equity of 7.7% beat Celcuity, Inc.'s return on equity of -158.5%.

Arrowhead Pharmaceuticals, Inc. has a consensus price target of $81.92, signalling upside risk potential of 24.91%. On the other hand Celcuity, Inc. has an analysts' consensus of $110.50 which suggests that it could fall by -3.52%. Given that Arrowhead Pharmaceuticals, Inc. has higher upside potential than Celcuity, Inc., analysts believe Arrowhead Pharmaceuticals, Inc. is more attractive than Celcuity, Inc..

Arrowhead Pharmaceuticals, Inc. has a beta of 1.209, which suggesting that the stock is 20.893% more volatile than S&P 500. In comparison Celcuity, Inc. has a beta of 0.254, suggesting its less volatile than the S&P 500 by 74.611%.

Arrowhead Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Celcuity, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arrowhead Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Celcuity, Inc. pays out -- of its earnings as a dividend.

Arrowhead Pharmaceuticals, Inc. quarterly revenues are $256.5M, which are larger than Celcuity, Inc. quarterly revenues of --. Arrowhead Pharmaceuticals, Inc.'s net income of $16.1M is higher than Celcuity, Inc.'s net income of -$43.8M. Notably, Arrowhead Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Celcuity, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arrowhead Pharmaceuticals, Inc. is 10.56x versus -- for Celcuity, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Ionis Pharmaceuticals, Inc. has a net margin of 6.29% compared to Arrowhead Pharmaceuticals, Inc.'s net margin of -82.06%. Arrowhead Pharmaceuticals, Inc.'s return on equity of 7.7% beat Ionis Pharmaceuticals, Inc.'s return on equity of -43.01%.

Arrowhead Pharmaceuticals, Inc. has a consensus price target of $81.92, signalling upside risk potential of 24.91%. On the other hand Ionis Pharmaceuticals, Inc. has an analysts' consensus of $90.67 which suggests that it could grow by 10.68%. Given that Arrowhead Pharmaceuticals, Inc. has higher upside potential than Ionis Pharmaceuticals, Inc., analysts believe Arrowhead Pharmaceuticals, Inc. is more attractive than Ionis Pharmaceuticals, Inc..

Arrowhead Pharmaceuticals, Inc. has a beta of 1.209, which suggesting that the stock is 20.893% more volatile than S&P 500. In comparison Ionis Pharmaceuticals, Inc. has a beta of 0.278, suggesting its less volatile than the S&P 500 by 72.158%.

Arrowhead Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arrowhead Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Ionis Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Arrowhead Pharmaceuticals, Inc. quarterly revenues are $256.5M, which are larger than Ionis Pharmaceuticals, Inc. quarterly revenues of $156.7M. Arrowhead Pharmaceuticals, Inc.'s net income of $16.1M is higher than Ionis Pharmaceuticals, Inc.'s net income of -$128.6M. Notably, Arrowhead Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Ionis Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arrowhead Pharmaceuticals, Inc. is 10.56x versus 13.95x for Ionis Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of 6.29% compared to Arrowhead Pharmaceuticals, Inc.'s net margin of 31.72%. Arrowhead Pharmaceuticals, Inc.'s return on equity of 7.7% beat Eli Lilly & Co.'s return on equity of 106.26%.

Arrowhead Pharmaceuticals, Inc. has a consensus price target of $81.92, signalling upside risk potential of 24.91%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,133.93 which suggests that it could grow by 10.76%. Given that Arrowhead Pharmaceuticals, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Arrowhead Pharmaceuticals, Inc. is more attractive than Eli Lilly & Co..

Arrowhead Pharmaceuticals, Inc. has a beta of 1.209, which suggesting that the stock is 20.893% more volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.348, suggesting its less volatile than the S&P 500 by 65.185%.

Arrowhead Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.59% to investors and pays a quarterly dividend of $1.50 per share. Arrowhead Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Arrowhead Pharmaceuticals, Inc. quarterly revenues are $256.5M, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Arrowhead Pharmaceuticals, Inc.'s net income of $16.1M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Arrowhead Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 50.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arrowhead Pharmaceuticals, Inc. is 10.56x versus 15.71x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics, Inc. has a net margin of 6.29% compared to Arrowhead Pharmaceuticals, Inc.'s net margin of -45.06%. Arrowhead Pharmaceuticals, Inc.'s return on equity of 7.7% beat Sarepta Therapeutics, Inc.'s return on equity of -20.67%.

Arrowhead Pharmaceuticals, Inc. has a consensus price target of $81.92, signalling upside risk potential of 24.91%. On the other hand Sarepta Therapeutics, Inc. has an analysts' consensus of $21.43 which suggests that it could grow by 0.59%. Given that Arrowhead Pharmaceuticals, Inc. has higher upside potential than Sarepta Therapeutics, Inc., analysts believe Arrowhead Pharmaceuticals, Inc. is more attractive than Sarepta Therapeutics, Inc..

Arrowhead Pharmaceuticals, Inc. has a beta of 1.209, which suggesting that the stock is 20.893% more volatile than S&P 500. In comparison Sarepta Therapeutics, Inc. has a beta of 0.485, suggesting its less volatile than the S&P 500 by 51.536%.

Arrowhead Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arrowhead Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Sarepta Therapeutics, Inc. pays out -- of its earnings as a dividend.

Arrowhead Pharmaceuticals, Inc. quarterly revenues are $256.5M, which are smaller than Sarepta Therapeutics, Inc. quarterly revenues of $399.4M. Arrowhead Pharmaceuticals, Inc.'s net income of $16.1M is higher than Sarepta Therapeutics, Inc.'s net income of -$179.9M. Notably, Arrowhead Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Sarepta Therapeutics, Inc.'s PE ratio is 20.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arrowhead Pharmaceuticals, Inc. is 10.56x versus 0.91x for Sarepta Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.